Given the emerging complexity of post-translational regulation, it will be important for future studies to explore whether CMA-mediated degradation of YAP1 is influenced by other modifications, such as SUMOylation, methylation, and palmitoylation
Monitoring and Follow-Up Establish a structured monitoring schedule: Monthly visits during dose titration and the first 6 months Quarterly visits once stable, assessing weight, tolerability, and metabolic parameters Annual comprehensive evaluation including lipid panel, HbA1c (if diabetic), liver function tests, and cardiovascular risk assessment Regular monitoring allows early identification of plateaus, adverse effects, or emerging medical issues that may require intervention
PT-141 10 mg Research-grade lyophilized peptide powder supplied in a sterile glass vial
Tirzepatide pricing varies by source and insurance coverage